HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist Hospital (HMH)
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
Coya Therapeutics Presents ALS Biomarker Data at Conference
Coya Therapeutics to Participate in BTIG Fireside Discussion
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in FTD
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg)
Coya Therapeutics to Present Biomarker Survival Data in Large Cohort of ALS